REGULATORY
AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
COVID-19 vaccines from AstraZeneca and Moderna will come up for discussion at a key health ministry panel meeting on May 20, which could pave the way for their respective exceptional approval soon after.Currently, Pfizer’s Comirnaty…

LATEST

May 17, 2021
Japan’s top four drug wholesalers suffered dismal earnings in their pharmaceutical wholesale business in FY2020 in the face of COVID-19 and intensified price battles, a Jiho tally showed. Their average operating margin fell far below 1%, which is seen as…
May 17, 2021
Two employees of Ono Pharmaceutical on May 14 admitted the charges of bribery they face for giving 2 million yen to a university hospital professor in the name of scholarship donations (shogaku-kifu) to boost prescriptions…
May 17, 2021
The Japanese government on May 14 clinched a pact with Pfizer to receive a supply of 50 million extra doses of its COVID-19 vaccine Comirnaty by the end of September, which will come on top…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Takashi Ohama

The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Eric Persoff

The past month has seen two significant milestones in healthcare price control measures in Japan: The first “off-year” NHI reimbursement price cuts, and release of the first results under Japan’s “cost-effectiveness assessment” system. Both milestones have been anticipated for quite…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA